Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125323241 | 12532324 | 1 | I | 20160621 | 20160622 | 20160706 | 20160706 | EXP | JP-PFIZER INC-2016314125 | PFIZER | 83.00 | YR | M | Y | 0.00000 | 20160706 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125323241 | 12532324 | 1 | PS | TOVIAZ | FESOTERODINE FUMARATE | 1 | Oral | 4 MG, DAILY | 22030 | 4 | MG | PROLONGED-RELEASE TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125323241 | 12532324 | 1 | Hypertonic bladder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125323241 | 12532324 | HO |
| 125323241 | 12532324 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125323241 | 12532324 | Prostate cancer | |
| 125323241 | 12532324 | Prostatic specific antigen increased | |
| 125323241 | 12532324 | Urinary retention |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125323241 | 12532324 | 1 | 20160620 | 20160621 | 0 |